Retatrutide appears to be a new medication in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By activating these mots-c dosing receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultimately leads to significant weight loss